Peer Review reports
From: Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
| Original Submission | ||
|---|---|---|
| 28 Jan 2022 | Submitted | Original manuscript |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| Resubmission - Version 3 | ||
| Submitted | Manuscript version 3 | |
| 28 Feb 2022 | Reviewed | Reviewer Report |
| 7 Mar 2022 | Reviewed | Reviewer Report |
| 25 Mar 2022 | Author responded | Author comments - Taoufik Alsaadi |
| Resubmission - Version 4 | ||
| 25 Mar 2022 | Submitted | Manuscript version 4 |
| 29 Mar 2022 | Author responded | Author comments - Taoufik Alsaadi |
| Resubmission - Version 5 | ||
| 29 Mar 2022 | Submitted | Manuscript version 5 |
| 2 Apr 2022 | Reviewed | Reviewer Report |
| 14 Apr 2022 | Author responded | Author comments - Taoufik Alsaadi |
| Resubmission - Version 6 | ||
| 14 Apr 2022 | Submitted | Manuscript version 6 |
| 19 Apr 2022 | Reviewed | Reviewer Report |
| 5 May 2022 | Reviewed | Reviewer Report |
| Resubmission - Version 7 | ||
| Submitted | Manuscript version 7 | |
| Publishing | ||
| 9 May 2022 | Editorially accepted | |
| 16 Jun 2022 | Article published | 10.1186/s12883-022-02710-5 |
You can find further information about peer review here.